Previously, we reported the sequence of a bispecific killer cell engager (BiKE) that targets the CD16a activating receptor on natural killer (NK) cells and the human epidermal growth factor receptor 2 (HER2) on cancer cells [4]. This evidence concerns the gene ERBB2 and cancer.